A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13635
Abstract: To compare the cost‐effectiveness of secukinumab vs adalimumab at 1 and 2 years of treatment in patients with ankylosing spondylitis (AS) by analyzing the cost per responder reported in randomized controlled trials (RCTs) from the… read more here.
Keywords: cost per; korean perspective; ankylosing spondylitis; per responder ... See more keywords